Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh

Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) lea...

Full description

Bibliographic Details
Main Author:	Md Noh, Siti Munirah
Format:	Book Section
Language:	English
Published:	Institute of Graduate Studies, UiTM 2018
Subjects:	RC Internal Medicine RM Therapeutics. Pharmacology
Online Access:	http://ir.uitm.edu.my/id/eprint/20553/ http://ir.uitm.edu.my/id/eprint/20553/1/ABS_SITI%20MUNIRAH%20MD%20NOH%20TDRA%20VOL%2013%20IGS%2018.pdf

id	uitm-20553
recordtype	eprints
spelling	uitm-205532018-07-06T05:58:56Z http://ir.uitm.edu.my/id/eprint/20553/ Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh Md Noh, Siti Munirah RC Internal Medicine RM Therapeutics. Pharmacology Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) leads to significant cases of surgical failure. Anti-vascular endothelial growth factor (VEGF) has become the focus in current scar modulation strategy. Improved bleb morphology following trabeculectomy augmented with ranibizumab has been reported. However, mechanism of actions of ranibizumab on HTF is not well understood. Therefore, this in vitro study was conducted to elucidate mechanism of actions of ranibizumab on HTF. HTF used in this study were propagated from Tenon’s capsule obtained from patients undergoing trabeculectomy. Firstly, isolated and characterized HTF were treated with different concentrations of ranibizumab in serum and serum-free media for 24 and 48 hours and then HTF viability was measured using MTT assay. Then, HTF were extracted to measure the expression of collagen Type 1 (COL1A1), fibronectin (FN), transforming growth factor-β1 and -β2 (TGF-β1 &TGF-β2) using qRT-PCR and ELISA. The experiment was followed with metabolomics profiling which was performed to identify the most significant metabolite regulated by ranibizumab… Institute of Graduate Studies, UiTM 2018 Book Section PeerReviewed text en http://ir.uitm.edu.my/id/eprint/20553/1/ABS_SITI%20MUNIRAH%20MD%20NOH%20TDRA%20VOL%2013%20IGS%2018.pdf Md Noh, Siti Munirah (2018) Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh. In: The Doctoral Research Abstracts. IGS Biannual Publication, 18 (18). Institute of Graduate Studies, UiTM, Shah Alam.
repository_type	Digital Repository
institution_category	Local University
institution	Universiti Teknologi MARA
building	UiTM Institutional Repository
collection	Online Access
language	English
topic	RC Internal Medicine RM Therapeutics. Pharmacology
spellingShingle	RC Internal Medicine RM Therapeutics. Pharmacology Md Noh, Siti Munirah Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
description	Trabeculectomy is the gold standard procedure performed in glaucoma when topical medication and laser intervention fail to maintain the ideal intraocular pressure (IOP) of patient’s eye. However, excessive accumulation of extracellular matrix components (ECM) mediated by Tenon’s fibroblast (HTF) leads to significant cases of surgical failure. Anti-vascular endothelial growth factor (VEGF) has become the focus in current scar modulation strategy. Improved bleb morphology following trabeculectomy augmented with ranibizumab has been reported. However, mechanism of actions of ranibizumab on HTF is not well understood. Therefore, this in vitro study was conducted to elucidate mechanism of actions of ranibizumab on HTF. HTF used in this study were propagated from Tenon’s capsule obtained from patients undergoing trabeculectomy. Firstly, isolated and characterized HTF were treated with different concentrations of ranibizumab in serum and serum-free media for 24 and 48 hours and then HTF viability was measured using MTT assay. Then, HTF were extracted to measure the expression of collagen Type 1 (COL1A1), fibronectin (FN), transforming growth factor-β1 and -β2 (TGF-β1 &TGF-β2) using qRT-PCR and ELISA. The experiment was followed with metabolomics profiling which was performed to identify the most significant metabolite regulated by ranibizumab…
format	Book Section
author	Md Noh, Siti Munirah
author_facet	Md Noh, Siti Munirah
author_sort	Md Noh, Siti Munirah
title	Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_short	Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_full	Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_fullStr	Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_full_unstemmed	Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh
title_sort	mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / siti munirah md noh
publisher	Institute of Graduate Studies, UiTM
publishDate	2018
url	http://ir.uitm.edu.my/id/eprint/20553/ http://ir.uitm.edu.my/id/eprint/20553/1/ABS_SITI%20MUNIRAH%20MD%20NOH%20TDRA%20VOL%2013%20IGS%2018.pdf
first_indexed	2023-09-18T23:04:49Z
last_indexed	2023-09-18T23:04:49Z
_version_	1777418412815810560

Mechanisms of ranibizumab as an anti-scarring agent in trabeculectomy / Siti Munirah Md Noh

Similar Items